Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	16/NE/0384	209045	A multi-center, randomized, double-blind, active-controlled, parallel group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in patients with left ventricular dysfunction following an acute myocardial infarction	Range Agreed	5	40	Date Agreed	31/03/2020	37	37	31/03/2020	Recruitment finished	
2	17/EM/0122	224376	A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)	Number Agreed	1	1	Date Agreed	04/10/2020	0	0	06/02/2020	Withdrawn by sponsor	This is a rare disease study and no patient presented at Newcastle before the sponsor reached their target globally
3	16/LO/2126	218039	A randomized trial comparing the ELUVIA™ drug-eluting stent versus bare Metal self-expanding nitINol stEnts in the treatmeNt of superficial femoral and/or proximal popliteal arTeries	Range Agreed	5	10	Date Agreed	31/03/2020	5	5	31/03/2020	Recruitment finished	
4	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization	Number Agreed	1	1	Date Agreed	02/06/2021	0	0	16/01/2020	Withdrawn by sponsor	Sponsor reached the required number of evaluable subjects to power the primary analysis appropriately.
5	16/LO/2002	214578	A Double-Blind, Placebo-Controlled, Multicenter Study with an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy	Range Agreed	1	5	Date Agreed	21/07/2020	5	5	21/01/2020	Recruitment finished	
6	17/YH/0426	231118	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients, =6 Years to <12 Years Of Age, with Severe Atopic Dermatitis	Number Agreed	3	3	Date Agreed	31/03/2020	0	0	31/03/2020	Withdrawn by sponsor	The study was halted early as the global target was reached ahead of time
7	18/NE/0194	242874	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in HemodynamIcally Stable Patients with Type 2 Diabetes Post Worsening Heart Failure	Range Agreed	1	5	Date Agreed	31/10/2020	1	1	24/03/2020	Withdrawn by sponsor	Notification that the study had ended globally
8	18/NE/0309	252961	An Open-Label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment with Oral REN001 in Patients with Primary Mitochondrial Myopathy (PMM), with an Optional Extension of Treatment	Range Agreed	8	14	Date Agreed	15/01/2020	12	12	15/01/2020	Recruitment finished	
9	18/LO/1542	247189	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis	Range Agreed	1	4	Date Agreed	14/02/2020	0	0	03/01/2020	Withdrawn by sponsor	Sponsor closed the study locally as recruitment was reached globally
10	19/EE/0124	260061	Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis	Range Agreed	1	2	Date Agreed	05/03/2020	1	1	04/03/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
11	19/NI/0110	260538	EluNIR Ridaforolimus Eluting Coronary Stent System in patients at high bleeding risk (HBR)– EluNIR HBR study	Range Agreed	1	2	Date Agreed	01/09/2020	0	0	29/02/2020	Recruitment finished	Recruitment finished with no recruits however, sponsor had decided on a 0 to 2 target
12	19/LO/1035	264950	A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis	Number Agreed	2	2	Date Agreed	31/07/2020	2	2	27/03/2020	Recruitment finished	
13	19/NE/0115	255707	An Open Label, Multi-Centre, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis	Range Agreed	3	10	Date Agreed	31/03/2020	10	10	23/03/2020	Recruitment finished	
14	19/HRA/7127	275934	Long term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long term follow-up (IMPRESS II)	Range Agreed	15	25	Date Agreed	29/02/2020	25	25	29/02/2020	Recruitment finished	
15	17/EE/0400	224645	A Multicenter, Randomized, Double-Blind,Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease	Range Agreed	3	6	Date Agreed	30/03/2020	3	3	30/03/2020	Recruitment finished	
16	16/NE/0147	204478	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis	Range Agreed	5	20	Date Agreed	31/05/2020	6	6	31/05/2020	Recruitment finished	
17	16/NE/0413	210215	Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.	Range Agreed	3	6	Date Agreed	01/06/2020	3	3	01/06/2020	Recruitment finished	
18	14/NE/1099	144103	Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study To Evaluate The Efficacy And Safety Of Etrolizumab Compared With Infliximab In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Naive To TNF Inhibitors	Range Agreed	4	10	Date Agreed	31/12/2021	7	7	14/04/2020	Recruitment finished	
19	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Range Agreed	1	3	Date Agreed	29/05/2020	2	2	29/05/2020	Recruitment finished	
20	17/YH/0391	229417	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	Range Agreed	2	5	Date Agreed	30/04/2020	3	3	30/04/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
21	18/LO/1925	250709	A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLEDUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND COMPARED WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Number Agreed	1	1	Date Agreed	15/10/2020	0	0	01/05/2020	Withdrawn by sponsor	
22	18/LO/1927	242927	A PHASE II OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE	Range Agreed	1	2	Date Agreed	31/10/2020	0	0	01/05/2020	Withdrawn by sponsor	Following USM to suspend follow up & Recruitment Protocol amendment adds management of COVID-19 patients as well as incorporating protocol clarification letters 1 & 2. This study is pending close out, no patients were recruited or planned to be recruited
23	19/SC/0148	260130	XTEND – evaluation of an eXtended and proactive dosing regimEn in treatment-Naïve patients with wet age related macular Degeneration (wAMD)	Number Agreed	30	30	Date Agreed	15/05/2020	30	30	28/04/2020	Recruitment finished	
24	18/SW/0214	249435	A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies	Number Agreed	10	10	Date Agreed	31/12/2024	11	11	20/04/2020	Recruitment finished	
25	19/NW/0540	269907	A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis	Number Agreed	2	2	Date Agreed	31/03/2020	2	2	31/03/2020	Recruitment finished	
26	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	Number Agreed	2	2	Date Agreed	21/05/2020	2	2	21/05/2020	Recruitment finished	
27	18/YH/0349	243300	Pyruvate Kinase Deficiency Global Longitudinal Registry	Number Agreed	2	2	Date Agreed	28/12/2024	3	3	06/04/2020	Recruitment finished	
28	18/SC/0240	230920	A Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of gantenerumab in patients with prodromal to mild Alzheimer's Disease	Range Agreed	2	4	Date Agreed	30/06/2020	2	2	19/06/2020	Recruitment finished	
29	18/SS/0144	248553	An open-label, non-investigational product, multi-centre, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX (FIX) prophylaxis replacement therapy in the usual care setting of moderately severe to severe adult haemophilia B subjects (FIX:C≤2%) who are negative for neutralising antibodies (NAB) to adeno-associated virus vector (AAV)-spark100	Number Agreed	2	2	Date Agreed	30/05/2020	1	1	31/03/2020	Recruitment finished	Global recruitment was reached and the study closed to recruitment at Newcastle

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
30	17/SC/0345	225047	A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections	Number Agreed	2	2	Date Agreed	01/07/2020	1	1	01/07/2020	Recruitment finished	Study closed internationally before we were able to recruit more participants
31	17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Range Agreed	1	2	Date Agreed	20/07/2020	2	2	01/07/2020	Recruitment finished	
32	18/SW/0049	237051	A Multicenter, Open-Label, Phase 1B/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination with Chemotherapy with or without Other Anti-Cancer Immunotherapies as First-Line Treatment in Patients with Advanced Malignancies	Number Agreed	4	4	Date Agreed	06/09/2020	4	4	12/08/2020	Recruitment finished	
33	18/EM/0005	236933	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Number Agreed	5	5	Date Agreed	31/03/2021	5	5	10/08/2020	Recruitment finished	
34	17/SC/0491	228055	A Phase 1-2, Open-Label, Dose-Finding, Proof Of Concept, First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CX-2009 In Adults With Metastatic Or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)	Number Agreed	4	4	Date Agreed	31/05/2020	1	1	09/04/2020	Withdrawn by sponsor	CytomX decided to close Study CTMX-M-2009-001 to screening and enrollment, based an assessment of the continued challenges for clinical trial execution in the current COVID-19 pandemic environment and the ongoing demands the pandemic placed on the health care system
35	18/NE/0235	244048	A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	5	5	Date Agreed	31/08/2020	5	5	31/08/2020	Recruitment finished	
36	18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	3	3	Date Agreed	18/12/2020	5	5	21/08/2020	Recruitment finished	
37	18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	5	Date Agreed	30/08/2020	0	0	02/07/2020	Withdrawn by sponsor	Complexa decided to terminate the study CXA-10-301 (PRIMEx) due to delays in recruitment of PRIMEx patients, creating a minimum 6 month delay due to COVID-19
38	18/LO/1859	252363	Observational cohort study of patients with hormone receptor-positive metastatic breast cancer treated with palbociclib (Ibrance®) as part of the United Kingdom Ibrance® Patient Program (IPP); the Real Outcomes Ibrance® Study (ROIS)	Range Agreed	7	13	Date Agreed	28/02/2021	10	10	03/08/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
39	19/NE/0076	242027	BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	Range Agreed	5	15	Date Agreed	31/10/2020	9	9	14/07/2020	Recruitment finished	
40	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	30/06/2020	0	0	26/05/2020	Withdrawn by sponsor	Study was closed to recruitment nationally because of COVID-19
41	18/LO/1397	247266	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	Range Agreed	2	4	Date Agreed	12/09/2020	0	0	04/09/2020	Withdrawn by sponsor	The sponsor took a decision to terminate the program
42	19/SC/0256	263749	A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients	Number Agreed	6	6	Date Agreed	09/10/2020	0	0	25/08/2020	Withdrawn by sponsor	In the UK we were slower to reactivate sites after the lockdown and other centers abroad recruited faster
43	19/EE/0135	252796	A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan with HM30181A Monotherapy in Patients with Advanced Malignancies	Range Agreed	6	16	Date Agreed	01/08/2020	1	1	15/06/2020	Withdrawn by sponsor	Sponsor closed recruitment unexpectedly early
44	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	Range Agreed	3	6	Date Agreed	31/10/2020	5	5	22/07/2020	Recruitment finished	
45	16/EM/0240	203358	A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma	Number Agreed	3	3	Date Agreed	01/03/2024	0	0	05/08/2020	Withdrawn by sponsor	The study closed nationally as interim analysis showed futility of the trial therapy
46	16/WM/0437	206885	A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Range Agreed	1	3	Date Agreed	21/08/2020	2	2	21/08/2020	Recruitment finished	
47	17/NW/0247	222303	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis	Range Agreed	2	4	Date Agreed	30/09/2020	1	1	12/08/2020	Withdrawn by sponsor	The sponsor took the decision to close the AURORA study and discontinue its NASH cenicriviroc [CVC] research & development program following the completion and analysis of the Part 1 section of the AURORA Phase III study.
48	17/EE/0402	224923	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991 Incorporating Administrative Change 1 and Amendment 1 and 2	Range Agreed	1	7	Date Agreed	12/11/2020	4	4	13/05/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
49	17/WM/0282	225240	A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT	Number Agreed	1	1	Date Agreed	01/01/2020	1	1	01/01/2020	Recruitment finished	
50	17/WM/0460	237521	PROJECT TITLE: Cabozantinib PASS Study- F-FR-60000-001 Prospective non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Range Agreed	7	10	Date Agreed	30/09/2020	7	7	30/09/2020	Recruitment finished	
51	18/ES/0029	239530	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Range Agreed	2	4	Date Agreed	31/07/2021	1	1	31/12/2020	Withdrawn by sponsor	The sponsor closed to recruitment earlier than planned in December following the interim analysis
52	17/NE/0331	229957	A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda™ device	Range Agreed	1	20	Date Agreed	31/12/2020	6	6	31/12/2020	Recruitment finished	
53	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy®	Number Agreed	50	50	Date Agreed	31/12/2020	14	14	31/12/2020	Withdrawn by sponsor	Sponsor closed the study early (from company end) due to commercial realignment of strategy.
54	18/NE/0292	252024	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study	Number Agreed	4	4	Date Agreed	06/10/2020	4	4	06/10/2020	Recruitment finished	
55	19/LO/0153	259690	A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or II	Number Agreed	2	2	Date Agreed	02/10/2020	2	2	02/10/2020	Recruitment finished	
56	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Number Agreed	2	2	Date Agreed	12/04/2022	1	1	31/12/2020	Recruitment finished	Recruitment finished early nationally
57	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	Range Agreed	5	20	Date Agreed	31/10/2020	6	6	02/10/2020	Recruitment finished	
58	18/NE/0264	250542	Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo single masked parallel trial (TRACKER)	Number Agreed	2	2	Date Agreed	31/03/2020	0	0	31/03/2020	Withdrawn by sponsor	Notification that the sponsor had closed the study

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
59	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection "ILIAD 7 trial"	Range Agreed	1	3	Date Agreed	25/11/2020	3	3	25/11/2020	Recruitment finished	
60	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	Number Agreed	5	5	Date Agreed	18/12/2020	2	2	13/12/2020	Recruitment finished	Recruitment ended early nationally
61	12/YH/0313	106560	A European multi-centre, multi-country, post-authorisation, observational study (registry) of patients with chronic adrenal insufficiency	Range Agreed	200	300	Date Agreed	31/12/2022	271	271	31/10/2020	Recruitment finished	